<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="600">
	<fontspec id="0" size="10" family="MinionPro" color="#231f20"/>
	<fontspec id="1" size="9" family="MinionPro" color="#231f20"/>
	<fontspec id="2" size="9" family="MinionMath" color="#231f20"/>
	<fontspec id="3" size="6" family="MinionPro" color="#231f20"/>
	<fontspec id="4" size="10" family="MinionPro" color="#000000"/>
<text top="44" left="51" width="5" height="10" font="0">4</text>
<text top="44" left="406" width="142" height="10" font="0">International Journal of Hepatology</text>
<text top="74" left="87" width="425" height="9" font="1">Table 2: Clinical and biochemical characteristics of 209 subjects with NAFLD divided by serum cytokeratin-18 tertiles.</text>
<text top="93" left="320" width="79" height="9" font="1">Cytokeratin-18 tertiles</text>
<text top="96" left="532" width="6" height="12" font="2">𝑃</text>
<text top="105" left="259" width="3" height="9" font="1">I</text>
<text top="105" left="353" width="6" height="9" font="1">II</text>
<text top="105" left="450" width="9" height="9" font="1">III</text>
<text top="118" left="53" width="36" height="9" font="1">Males (%)</text>
<text top="118" left="254" width="14" height="9" font="1">68.1</text>
<text top="118" left="349" width="15" height="9" font="1">63.0</text>
<text top="118" left="447" width="15" height="9" font="1">62.7</text>
<text top="118" left="531" width="8" height="9" font="1">ns</text>
<text top="132" left="53" width="33" height="9" font="1">Age (yrs)</text>
<text top="130" left="241" width="39" height="12" font="2">53.8 ± 12.9</text>
<text top="130" left="337" width="39" height="12" font="2">54.7 ± 10.9</text>
<text top="130" left="435" width="39" height="12" font="2">54.2 ± 12.3</text>
<text top="132" left="531" width="8" height="9" font="1">ns</text>
<text top="145" left="53" width="85" height="9" font="1">Body mass index (kg/m</text>
<text top="143" left="137" width="3" height="6" font="3">2</text>
<text top="145" left="141" width="3" height="9" font="1">)</text>
<text top="143" left="244" width="35" height="12" font="2">27.2 ± 3.9</text>
<text top="143" left="339" width="35" height="12" font="2">31.6 ± 3.3</text>
<text top="143" left="437" width="35" height="12" font="2">36.1 ± 5.4</text>
<text top="143" left="523" width="5" height="12" font="2">&lt;</text>
<text top="145" left="528" width="18" height="9" font="1">0.001</text>
<text top="159" left="53" width="72" height="9" font="1">Urinary 8-iso-PGF2</text>
<text top="156" left="124" width="5" height="12" font="2">𝛼</text>
<text top="159" left="131" width="67" height="9" font="1">(pg/mg creatinine)</text>
<text top="156" left="237" width="48" height="12" font="2">616.7 ± 122.9</text>
<text top="156" left="335" width="43" height="12" font="2">727.5 ± 82.1</text>
<text top="156" left="433" width="43" height="12" font="2">800.9 ± 82.1</text>
<text top="156" left="523" width="5" height="12" font="2">&lt;</text>
<text top="159" left="528" width="18" height="9" font="1">0.001</text>
<text top="172" left="53" width="39" height="9" font="1">HOMA-IR</text>
<text top="172" left="240" width="42" height="9" font="1">2.8 (1.9/4.0)</text>
<text top="172" left="335" width="42" height="9" font="1">3.2 (2.4/5.7)</text>
<text top="172" left="434" width="41" height="9" font="1">5.3 (3.4/7.3)</text>
<text top="170" left="523" width="5" height="12" font="2">&lt;</text>
<text top="172" left="528" width="18" height="9" font="1">0.001</text>
<text top="185" left="53" width="91" height="9" font="1">Total cholesterol (mg/dL)</text>
<text top="183" left="239" width="43" height="12" font="2">201.4 ± 38.4</text>
<text top="183" left="335" width="43" height="12" font="2">196.9 ± 38.5</text>
<text top="183" left="433" width="43" height="12" font="2">201.4 ± 41.5</text>
<text top="185" left="531" width="8" height="9" font="1">ns</text>
<text top="199" left="53" width="50" height="9" font="1">HDL (mg/dL)</text>
<text top="199" left="243" width="36" height="9" font="1">50 (43/61)</text>
<text top="199" left="338" width="37" height="9" font="1">47 (38/54)</text>
<text top="199" left="437" width="35" height="9" font="1">43 (39/51)</text>
<text top="197" left="525" width="5" height="12" font="2">&lt;</text>
<text top="199" left="530" width="15" height="9" font="1">0.05</text>
<text top="212" left="53" width="78" height="9" font="1">Triglycerides (mg/dL)</text>
<text top="212" left="230" width="61" height="9" font="1">125.5 (85.5/160.3)</text>
<text top="212" left="327" width="58" height="9" font="1">138 (102.0/180.5)</text>
<text top="212" left="421" width="66" height="9" font="1">165.0 (125.0/206.0)</text>
<text top="210" left="525" width="5" height="12" font="2">&lt;</text>
<text top="212" left="531" width="14" height="9" font="1">0.01</text>
<text top="224" left="53" width="4" height="12" font="2">𝛾</text>
<text top="226" left="57" width="41" height="9" font="1">-GT (IU/L)</text>
<text top="226" left="237" width="48" height="9" font="1">23 (16.8/36.5)</text>
<text top="226" left="333" width="47" height="9" font="1">27 (17.5/44.0)</text>
<text top="226" left="437" width="35" height="9" font="1">30 (18/53)</text>
<text top="226" left="531" width="8" height="9" font="1">ns</text>
<text top="240" left="53" width="42" height="9" font="1">ALT (IU/L)</text>
<text top="240" left="240" width="42" height="9" font="1">31 (22.8/40)</text>
<text top="240" left="335" width="42" height="9" font="1">28 (20/41.5)</text>
<text top="240" left="436" width="37" height="9" font="1">26 (20/40)</text>
<text top="240" left="531" width="8" height="9" font="1">ns</text>
<text top="254" left="53" width="42" height="9" font="1">AST (IU/L)</text>
<text top="254" left="243" width="35" height="9" font="1">22 (18/28)</text>
<text top="254" left="336" width="40" height="9" font="1">21 (17/26.5)</text>
<text top="254" left="437" width="34" height="9" font="1">21 (17/28)</text>
<text top="254" left="531" width="8" height="9" font="1">ns</text>
<text top="267" left="53" width="77" height="9" font="1">Adiponectin (ng/mL)</text>
<text top="267" left="239" width="45" height="9" font="1">12 (10.4/14.1)</text>
<text top="267" left="334" width="44" height="9" font="1">7.5 (5.5/10.5)</text>
<text top="267" left="442" width="24" height="9" font="1">5 (4/7)</text>
<text top="265" left="523" width="5" height="12" font="2">&lt;</text>
<text top="267" left="528" width="18" height="9" font="1">0.001</text>
<text top="281" left="53" width="71" height="9" font="1">sNOX2-dp (pg/mL)</text>
<text top="281" left="239" width="43" height="9" font="1">49 (40/58.3)</text>
<text top="281" left="337" width="38" height="9" font="1">60 (50/66)</text>
<text top="281" left="436" width="36" height="9" font="1">67 (64/71)</text>
<text top="279" left="523" width="5" height="12" font="2">&lt;</text>
<text top="281" left="528" width="18" height="9" font="1">0.001</text>
<text top="294" left="53" width="62" height="9" font="1">Hamaguchi score</text>
<text top="292" left="246" width="31" height="12" font="2">3.5 ± 1.3</text>
<text top="292" left="341" width="31" height="12" font="2">4.0 ± 1.3</text>
<text top="292" left="439" width="31" height="12" font="2">4.3 ± 1.3</text>
<text top="292" left="525" width="5" height="12" font="2">&lt;</text>
<text top="294" left="531" width="14" height="9" font="1">0.01</text>
<text top="307" left="53" width="89" height="9" font="1">Metabolic syndrome (%)</text>
<text top="307" left="254" width="15" height="9" font="1">49.4</text>
<text top="307" left="349" width="15" height="9" font="1">69.0</text>
<text top="307" left="447" width="15" height="9" font="1">84.8</text>
<text top="305" left="523" width="5" height="12" font="2">&lt;</text>
<text top="307" left="528" width="18" height="9" font="1">0.001</text>
<text top="321" left="53" width="46" height="9" font="1">Diabetes (%)</text>
<text top="321" left="254" width="15" height="9" font="1">20.3</text>
<text top="321" left="349" width="14" height="9" font="1">30.1</text>
<text top="321" left="447" width="15" height="9" font="1">43.3</text>
<text top="319" left="525" width="5" height="12" font="2">&lt;</text>
<text top="321" left="530" width="15" height="9" font="1">0.05</text>
<text top="354" left="51" width="240" height="9" font="1">Table 3: Correlations between serum cytokeratin-18 and some</text>
<text top="364" left="51" width="134" height="9" font="1">clinical and metabolic characteristics.</text>
<text top="381" left="214" width="53" height="9" font="1">Cytokeratin-18</text>
<text top="392" left="201" width="4" height="12" font="2">𝑟</text>
<text top="392" left="273" width="6" height="12" font="2">𝑃</text>
<text top="409" left="53" width="33" height="9" font="1">Age (yrs)</text>
<text top="408" left="194" width="18" height="9" font="1">0.031</text>
<text top="408" left="271" width="8" height="9" font="1">ns</text>
<text top="422" left="53" width="40" height="9" font="1">BMI (kg/m</text>
<text top="420" left="93" width="3" height="6" font="3">2</text>
<text top="422" left="96" width="3" height="9" font="1">)</text>
<text top="421" left="193" width="19" height="9" font="1">0.577</text>
<text top="419" left="264" width="5" height="12" font="2">&lt;</text>
<text top="421" left="269" width="18" height="9" font="1">0.001</text>
<text top="435" left="53" width="73" height="9" font="1">Waist circumference</text>
<text top="434" left="194" width="18" height="9" font="1">0.601</text>
<text top="432" left="264" width="5" height="12" font="2">&lt;</text>
<text top="434" left="269" width="18" height="9" font="1">0.001</text>
<text top="448" left="53" width="39" height="9" font="1">HOMA-IR</text>
<text top="448" left="194" width="17" height="9" font="1">0.191</text>
<text top="446" left="266" width="5" height="12" font="2">&lt;</text>
<text top="448" left="271" width="14" height="9" font="1">0.01</text>
<text top="461" left="53" width="78" height="9" font="1">Fasting blood glucose</text>
<text top="471" left="53" width="30" height="9" font="1">(mg/dL)</text>
<text top="465" left="194" width="18" height="9" font="1">0.216</text>
<text top="463" left="266" width="5" height="12" font="2">&lt;</text>
<text top="465" left="271" width="14" height="9" font="1">0.01</text>
<text top="485" left="53" width="91" height="9" font="1">Total cholesterol (mg/dL)</text>
<text top="484" left="193" width="19" height="9" font="1">0.036</text>
<text top="484" left="271" width="8" height="9" font="1">ns</text>
<text top="497" left="53" width="91" height="9" font="1">HDL cholesterol (mg/dL)</text>
<text top="494" left="191" width="5" height="12" font="2">−</text>
<text top="496" left="196" width="18" height="9" font="1">0.150</text>
<text top="494" left="265" width="5" height="12" font="2">&lt;</text>
<text top="496" left="271" width="15" height="9" font="1">0.05</text>
<text top="509" left="53" width="78" height="9" font="1">Triglycerides (mg/dL)</text>
<text top="508" left="194" width="18" height="9" font="1">0.100</text>
<text top="508" left="271" width="8" height="9" font="1">ns</text>
<text top="519" left="53" width="4" height="12" font="2">𝛾</text>
<text top="521" left="57" width="38" height="9" font="1">-GT (IU/l)</text>
<text top="521" left="194" width="18" height="9" font="1">0.137</text>
<text top="519" left="265" width="5" height="12" font="2">&lt;</text>
<text top="521" left="271" width="15" height="9" font="1">0.05</text>
<text top="534" left="53" width="39" height="9" font="1">AST (IU/l)</text>
<text top="531" left="191" width="5" height="12" font="2">−</text>
<text top="533" left="196" width="19" height="9" font="1">0.078</text>
<text top="533" left="271" width="8" height="9" font="1">ns</text>
<text top="546" left="53" width="39" height="9" font="1">ALT (UI/l)</text>
<text top="543" left="191" width="5" height="12" font="2">−</text>
<text top="545" left="196" width="19" height="9" font="1">0.039</text>
<text top="545" left="271" width="8" height="9" font="1">ns</text>
<text top="558" left="53" width="83" height="9" font="1">Serum ferritin (mg/dL)</text>
<text top="555" left="191" width="5" height="12" font="2">−</text>
<text top="557" left="196" width="18" height="9" font="1">0.106</text>
<text top="557" left="271" width="8" height="9" font="1">ns</text>
<text top="570" left="53" width="88" height="9" font="1">Serum albumin (mg/dL)</text>
<text top="568" left="190" width="5" height="12" font="2">−</text>
<text top="570" left="196" width="19" height="9" font="1">0.207</text>
<text top="568" left="266" width="5" height="12" font="2">&lt;</text>
<text top="570" left="271" width="14" height="9" font="1">0.01</text>
<text top="583" left="53" width="45" height="9" font="1">Adiponectin</text>
<text top="580" left="191" width="5" height="12" font="2">−</text>
<text top="582" left="196" width="19" height="9" font="1">0.455</text>
<text top="580" left="264" width="5" height="12" font="2">&lt;</text>
<text top="582" left="269" width="18" height="9" font="1">0.001</text>
<text top="594" left="53" width="72" height="9" font="1">Urinary 8-iso-PGF2</text>
<text top="592" left="124" width="5" height="12" font="2">𝛼</text>
<text top="605" left="53" width="67" height="9" font="1">(pg/mg creatinine)</text>
<text top="599" left="193" width="20" height="9" font="1">0.607</text>
<text top="597" left="264" width="5" height="12" font="2">&lt;</text>
<text top="599" left="269" width="18" height="9" font="1">0.001</text>
<text top="617" left="53" width="71" height="9" font="1">sNOX2-dp (pg/mL)</text>
<text top="616" left="194" width="18" height="9" font="1">0.451</text>
<text top="614" left="264" width="5" height="12" font="2">&lt;</text>
<text top="616" left="269" width="18" height="9" font="1">0.001</text>
<text top="629" left="53" width="62" height="9" font="1">Hamaguchi score</text>
<text top="628" left="194" width="18" height="9" font="1">0.194</text>
<text top="626" left="264" width="5" height="12" font="2">&lt;</text>
<text top="628" left="269" width="18" height="9" font="1">0.001</text>
<text top="641" left="53" width="58" height="9" font="1">Spleen diameter</text>
<text top="641" left="194" width="18" height="9" font="1">0.190</text>
<text top="639" left="265" width="5" height="12" font="2">&lt;</text>
<text top="641" left="271" width="15" height="9" font="1">0.05</text>
<text top="654" left="53" width="80" height="9" font="1">NAFLD Fibrosis score</text>
<text top="653" left="193" width="19" height="9" font="1">0.299</text>
<text top="651" left="264" width="5" height="12" font="2">&lt;</text>
<text top="653" left="269" width="18" height="9" font="1">0.001</text>
<text top="666" left="53" width="39" height="9" font="1">MetS score</text>
<text top="665" left="193" width="19" height="9" font="1">0.377</text>
<text top="663" left="264" width="5" height="12" font="2">&lt;</text>
<text top="665" left="269" width="18" height="9" font="1">0.001</text>
<text top="699" left="51" width="113" height="10" font="0">for every 50 U/L increase) <a href="">[</a></text>
<text top="699" left="164" width="10" height="10" font="4"><a href="">26</a></text>
<text top="699" left="173" width="118" height="10" font="0">]. Moreover, CK-18 fragment</text>
<text top="711" left="51" width="240" height="10" font="0">levels were validated as noninvasive biomarkers for NASH</text>
<text top="722" left="51" width="240" height="10" font="0">also in a multicenter study performed in a large, diverse</text>
<text top="733" left="51" width="207" height="10" font="0">population of patients with biopsy-proven NAFLD <a href="">[</a></text>
<text top="733" left="258" width="5" height="10" font="4"><a href="">7</a></text>
<text top="733" left="262" width="6" height="10" font="0">].</text>
<text top="354" left="324" width="225" height="10" font="0">Consistent with this theory, we found a significant cor-</text>
<text top="365" left="309" width="240" height="10" font="0">relation between CK-18 serum levels and NFS, an accurate,</text>
<text top="376" left="309" width="240" height="10" font="0">noninvasive scoring system based on routinely measured and</text>
<text top="388" left="309" width="240" height="10" font="0">readily available clinical and laboratory data, that identifies</text>
<text top="399" left="309" width="188" height="10" font="0">advanced liver fibrosis in patients with NAFLD <a href="">[</a></text>
<text top="399" left="496" width="9" height="10" font="4"><a href="">27</a></text>
<text top="399" left="506" width="43" height="10" font="0"><a href="">]. </a>Recently,</text>
<text top="410" left="309" width="240" height="10" font="0">NFS has been validated for predicting death or liver com-</text>
<text top="422" left="309" width="225" height="10" font="0">plications in NAFLD patients over long-term follow-up <a href="">[</a></text>
<text top="422" left="534" width="9" height="10" font="4"><a href="">28</a></text>
<text top="422" left="543" width="6" height="10" font="0">].</text>
<text top="433" left="309" width="240" height="10" font="0">To our knowledge, this is the first time that the association</text>
<text top="445" left="309" width="205" height="10" font="0">between serum CK-18 and NFS has been described.</text>
<text top="458" left="324" width="225" height="10" font="0">The finding of a strong independent positive association</text>
<text top="469" left="309" width="240" height="10" font="0">of two reliable markers of oxidative stress with a marker of</text>
<text top="481" left="309" width="240" height="10" font="0">hepatocyte apoptosis is consistent with the “two-hit” theory</text>
<text top="492" left="309" width="240" height="10" font="0">based on the prominent role of oxidative stress as a major</text>
<text top="503" left="309" width="240" height="10" font="0">player triggering the progression of steatosis to NASH. In fact,</text>
<text top="515" left="309" width="240" height="10" font="0">according to the “two hits hypothesis,” the development of</text>
<text top="526" left="309" width="240" height="10" font="0">NASH requires “two hits” to become manifested. The first</text>
<text top="537" left="309" width="240" height="10" font="0">one is represented by the development of steatosis, while</text>
<text top="549" left="309" width="240" height="10" font="0">the second hit is induced by a disbalance between oxidative</text>
<text top="560" left="309" width="240" height="10" font="0">stress and antioxidant systems, leading to cell injury and</text>
<text top="572" left="309" width="240" height="10" font="0">inflammation (i.e., steatohepatitis) and lipid peroxidation. In</text>
<text top="583" left="309" width="240" height="10" font="0">keeping with this theory, hepatocyte apoptosis is likely to be</text>
<text top="594" left="309" width="240" height="10" font="0">considered a component of the second hit. Accordingly, a</text>
<text top="606" left="309" width="240" height="10" font="0">working model in which apoptosis and formation of reactive</text>
<text top="617" left="309" width="159" height="10" font="0">oxygen species are caspase dependent <a href="">[</a></text>
<text top="617" left="467" width="5" height="10" font="4"><a href="">9</a></text>
<text top="617" left="472" width="77" height="10" font="0">], with final release</text>
<text top="628" left="309" width="240" height="10" font="0">of CK-18 fragments, has been proposed. Indeed, cell repair,</text>
<text top="640" left="309" width="240" height="10" font="0">inflammation, regeneration, and fibrosis typical of NASH</text>
<text top="651" left="309" width="240" height="10" font="0">may be triggered by hepatocyte apoptosis. A link between</text>
<text top="663" left="309" width="240" height="10" font="0">hepatocyte apoptosis and liver fibrogenesis is supported by</text>
<text top="674" left="309" width="157" height="10" font="0">both experimental and human studies <a href="">[</a></text>
<text top="674" left="465" width="5" height="10" font="4"><a href="">8</a></text>
<text top="674" left="470" width="6" height="10" font="0">].</text>
<text top="687" left="324" width="225" height="10" font="0">High serum CK-18 values were associated with high</text>
<text top="699" left="309" width="240" height="10" font="0">HOMA-IR, high fasting blood glucose and triglycerides, and</text>
<text top="710" left="309" width="240" height="10" font="0">low HDL cholesterol, that is, the metabolic features of MetS,</text>
<text top="721" left="309" width="240" height="10" font="0">whose prevalence in patients belonging to the top CK-18</text>
<text top="733" left="309" width="78" height="10" font="0">tertile reached 85%.</text>
</page>
</pdf2xml>
